Laras A - Search Results

1

In vivo suppression of precore mRNA synthesis is associated with mutations in the hepatitis B virus core promoter.

Laras A, Koskinas J, Hadziyannis SJ. Laras A, et al. Virology. 2002 Mar 30;295(1):86-96. doi: 10.1006/viro.2001.1352. Virology. 2002. PMID: 12033768 Free article.

2

Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease.

Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis SJ. Papatheodoridis GV, et al. Among authors: laras a. Hepatology. 2002 Jul;36(1):219-26. doi: 10.1053/jhep.2002.33894. Hepatology. 2002. PMID: 12085368

3

Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients.

Laras A, Koskinas J, Dimou E, Kostamena A, Hadziyannis SJ. Laras A, et al. Hepatology. 2006 Sep;44(3):694-702. doi: 10.1002/hep.21299. Hepatology. 2006. PMID: 16941694

4

Serum hepatitis B virus RNA detectability, composition and clinical significance in patients with ab initio hepatitis B e antigen negative chronic hepatitis B.

Laras A, Papatheodoridi M, Panopoulou E, Papatheodoridis GV, Hadziyannis SJ, Hadziyannis E. Laras A, et al. Virol J. 2022 Jan 29;19(1):22. doi: 10.1186/s12985-022-01749-7. Virol J. 2022. PMID: 35093105 Free PMC article.

5

Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen-negative patients.

Laras A, Koskinas J, Avgidis K, Hadziyannis SJ. Laras A, et al. J Viral Hepat. 1998 Jul;5(4):241-8. doi: 10.1046/j.1365-2893.1998.00109.x. J Viral Hepat. 1998. PMID: 9751010

6

Absence of the negative strand of GBV-C/HGV RNA from the liver.

Laras A, Zacharakis G, Hadziyannis SJ. Laras A, et al. J Hepatol. 1999 Mar;30(3):383-8. doi: 10.1016/s0168-8278(99)80094-4. J Hepatol. 1999. PMID: 10190718

7

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Hadziyannis SJ, et al. Among authors: laras a. Hepatology. 2000 Oct;32(4 Pt 1):847-51. doi: 10.1053/jhep.2000.17915. Hepatology. 2000. PMID: 11003633

8

Letter: do interferon lambda 3 polymorphisms predict the outcome of interferon therapy in hepatitis B infection?

Hadziyannis SJ, Laras A, Hadziyannis E. Hadziyannis SJ, et al. Among authors: laras a. Aliment Pharmacol Ther. 2014 May;39(10):1250-1. doi: 10.1111/apt.12719. Aliment Pharmacol Ther. 2014. PMID: 24735152 No abstract available.

9

HBeAg-negative hepatitis B in a previously thalassemic patient during immunosuppressive therapy for chronic GVHD.

Kostaridou S, Ladis V, Kattamis A, Laras A, Hadziyannis SJ. Kostaridou S, et al. Among authors: laras a. Bone Marrow Transplant. 1998 Nov;22(9):919-21. doi: 10.1038/sj.bmt.1701433. Bone Marrow Transplant. 1998. PMID: 9827822

10

Human immunodeficiency virus type 1 Tat-mediated trans activation correlates with the phosphorylation state of a cellular TAR RNA stem-binding factor.

Han XM, Laras A, Rounseville MP, Kumar A, Shank PR. Han XM, et al. Among authors: laras a. J Virol. 1992 Jul;66(7):4065-72. doi: 10.1128/JVI.66.7.4065-4072.1992. J Virol. 1992. PMID: 1602533 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

12 results

Search Page

Filters